← Back
Data updated: Mar 10, 2026
QILU
OncologyCardiovascularInfectious Disease
QILU is a generic drug manufacturer focused on Oncology, Cardiovascular, Infectious Disease. Key products include MEROPENEM.
2016
Since
17
Drugs
-
Trials
135
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
MEROPENEM 2026-02-17
Labeling
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
LENALIDOMIDE 2026-02-02
OLANZAPINE 2026-01-23
OLANZAPINE 2026-01-22
Labeling
CYCLOSPORINE 2026-01-21
MIRABEGRON 2026-01-20
OLANZAPINE 2026-01-06
Labeling
OLANZAPINE 2026-01-06
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 65%
4 drugs Phase 3: 16 Phase 2: 10 Phase 1: 24
Cardiovascular 11%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 3
Infectious Disease 10%
1 drugs Phase 3: 3 Phase 1: 2
Dermatology 7%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 3
Immunology 7%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Immunology, Oncology
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Cardiovascular
Active (12)
Discontinued (4)
Company Info
- First Approval
- 2016-01-27
- Latest
- 2026-02-17
- Applications
- 21
FDA Sponsor Names
QILUQILU PHARM CO LTD